Eisai Innovation, Inc. and MBC BioLabs Announce Golden Ticket Competition Winner
Eisai Innovation, Inc. and MBC BioLabs are happy to announce Sift Biosciences as the winner of their 2024 Golden Ticket Competition. Sift Biosciences will be provided free lab space for one year in the state-of-the-art MBC BioLabs laboratory facility in San Francisco, California, enabling them to pursue drug discovery and innovation for the potential future benefit of patients worldwide.
Entries were received across a broad range of disease areas and included a number of exciting, innovative technologies. Sift Biosciences was selected based on their Artificial intelligence (AI), metagenomics, and high-throughput screening approach to develop safer and more effective immune-activating molecules from billions of microbial genes.
About Sift Biosciences
Developing Next-Generation Immune Boosters Using AI and Microbial Memory
Sift Biosciences combines AI with high-throughput antigen screening to develop next-generation immunomodulators. The company’s immune boosters can supercharge anti-cancer responses, with the goal of delivering lasting remissions to patients. Sift’s initial focus is on gynecological cancers (GYN). Existing immunotherapies have limited success in GYN patients as the majority present with tumors that are immunologically “cold” due to a lack of highly immunogenic antigen targets. By leveraging, and redirecting, pre-existing immune-microbe interactions, Sift’s proprietary, microbially derived antigens can transform these “cold” tumors “hot,” leading to >50X improved immune responses against weakly immunogenic antigen targets. Sift’s boosters are safe, targeted, and durable, offering a promising new strategy in the battle against cancer.